Leukemia, Erythroblastic, Acute [clinicaltrials_resource:d8aa49d8f2b694f0bcc6a48289faffe8]
condition [clinicaltrials_vocabulary:condition]
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002798]Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00003190]Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00006363]Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00027872]Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00045435]Cilengitide in Treating Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00089388]S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00093418]Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00093470]XK469R in Treating Patients With Refractory Hematologic Cancer [clinicaltrials:NCT00095797]clinicaltrials:NCT00096122Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT00096148]Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes [clinicaltrials:NCT00098423]SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes [clinicaltrials:NCT00098826]Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00101140]Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia [clinicaltrials:NCT00101231]Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [clinicaltrials:NCT00101296]17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer [clinicaltrials:NCT00103272]Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT00112853]Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia [clinicaltrials:NCT00131989]Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00217646]7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes [clinicaltrials:NCT00301938]clinicaltrials:NCT00305773clinicaltrials:NCT00352365Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders [clinicaltrials:NCT00357305]clinicaltrials:NCT00369317Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase [clinicaltrials:NCT00383474]Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [clinicaltrials:NCT00392353]clinicaltrials:NCT00407966MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia [clinicaltrials:NCT00462605]Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia [clinicaltrials:NCT00470197]Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [clinicaltrials:NCT00588991]clinicaltrials:NCT00602771clinicaltrials:NCT00634244clinicaltrials:NCT00658814clinicaltrials:NCT00666588Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00673153]clinicaltrials:NCT00742625clinicaltrials:NCT00795002clinicaltrials:NCT00895934Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT01028716]
condition browse [clinicaltrials_vocabulary:condition-browse]
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002798]Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00003190]Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00006363]Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00027872]Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00045435]Cilengitide in Treating Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00089388]S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00093418]Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00093470]XK469R in Treating Patients With Refractory Hematologic Cancer [clinicaltrials:NCT00095797]clinicaltrials:NCT00096122Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT00096148]Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes [clinicaltrials:NCT00098423]SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes [clinicaltrials:NCT00098826]Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00101140]Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia [clinicaltrials:NCT00101231]Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [clinicaltrials:NCT00101296]17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer [clinicaltrials:NCT00103272]Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT00112853]Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia [clinicaltrials:NCT00131989]Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00217646]7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes [clinicaltrials:NCT00301938]clinicaltrials:NCT00305773clinicaltrials:NCT00352365Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders [clinicaltrials:NCT00357305]clinicaltrials:NCT00369317Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase [clinicaltrials:NCT00383474]Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [clinicaltrials:NCT00392353]clinicaltrials:NCT00407966MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia [clinicaltrials:NCT00462605]Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia [clinicaltrials:NCT00470197]Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [clinicaltrials:NCT00588991]clinicaltrials:NCT00602771clinicaltrials:NCT00634244clinicaltrials:NCT00658814clinicaltrials:NCT00666588Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00673153]clinicaltrials:NCT00742625clinicaltrials:NCT00795002clinicaltrials:NCT00895934Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT01028716]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Leukemia, Erythroblastic, Acute [clinicaltrials_resource:d8aa49d8f2b694f0bcc6a48289faffe8]
Bio2RDF identifier
d8aa49d8f2b694f0bcc6a48289faffe8
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d8aa49d8f2b694f0bcc6a48289faffe8
identifier
clinicaltrials_resource:d8aa49d8f2b694f0bcc6a48289faffe8
title
Leukemia, Erythroblastic, Acute
@en
type
label
Leukemia, Erythroblastic, Acut ...... a49d8f2b694f0bcc6a48289faffe8]
@en
Leukemia, Erythroblastic, Acute